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Summary: A five-year experience with the vasopressin analogue desmopressin acetate
(DDAVP) for nocturnal enuresis is described in 59 children. The initial starting dose
of 5 &mu;g at bedtime is lower than that reported in other series. Eighty-one percent of
patients required 10 &mu;g or less to achieve improvement or resolution of bedwetting.
Introduction
children throughout his-
~ tory have been distressed
by nocturnal enuresis, and
physicians have been frustrated in
their search for the ideal treat-
ment. Glicklichl described the tri-
als and tolls of bedwetting in the
19th century; frequent changes of
linen were impossible for poor
families and household friction led
to ill treatment, whereas bedwet-
ting children of high social station
were ineligible for boarding
schools. Treatments available in
that era included belladonna,
preparations of arsenic and steel,
and injection of ergot into the
ischiorectal fossa.
The point at which nocturnal
enuresis can fairly be described as
a disease varies according to family,
patient, and social situation. The
prevalence of nocturnal enuresis
in six-year-olds is estimated at 13%,
decreasing to 7% by age eight.2 In
the younger children it is difficult
to believe that bedwetting should
engender serious medical atten-
tion since left untreated, the spon-
taneous cure rate by age 14 is 98%
to 99%.3 However, by eight to ten
years of age, nocturnal enuresis has
significant costs in terms of self-es-
teem, inconvenience, and peer
standing.
Current treatments include blad-
der-retention training, psychother-
apy, motivational therapy, behavioral
modification, and pharmacologic in-
tervention. Desmopressin acetate
(DDAVP), a recent addition to the
pharmacologic armamentarium, is
a synthetic analogue of human ar-
ginine vasopressin (ADH). Dim-
son reported its use in children
with enuresis in 1977, and subse-
quent experience has established
its efficacy and safety at dosages of
20 to 40 Jig intranasally at bed-
time.~
Material and Methods
DDAVP was used in 59 patients
with nocturnal enuresis over a five-
year period. Forty boys and 19 girls,
8 to 20 years of age, with a mean of
12.5 years, made up the study
group. History, physical examina-
tion, blood pressure, urinalysis,
and urine specific gravity at the
initiation of treatment were nor-
mal for each patient. Patients with
such factors as excessive fluid in-
take, extraordinary headaches, or
cystic fibrosis were excluded. Forty-
seven patients were otherwise
healthy children and 12 had asso-
ciated medical problems consist-
ing ofvesicoureteral reflux, growth
hormone deficiency, seizure disor-
der, factor IX deficiency, unde-
scended testicle, hypertension,
testicular torsion, proteinuria, en-
copresis and mental retardation.
Fifty-one percent of patients had
received previous forms of treat-
ment consisting of anticholiner-
gics (17%), imipramine (57%),
and moisture-sensing alarms
(26%).
The initial starting dose of
DDAVP was 5 gg intranasally at
bedtime. If the initial 5 gg dose was
unsuccessful after two weeks, it was
increased to 10 gg. Instructions
and demonstration for use were
given by a nurse clinician. Patients
were requested to withhold intake
of fluids an hour before bedtime.
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Figure 1. Final dose of DDAVP.
Figure 2 . Wet nights per week pre- and posttreatment.
To administer the medication, the
nose was cleared of secretions and
debris, the medication was dis-
pensed to the proper dose level,
the delivery tube was placed just
inside the nose, and the dose was
briskly inhaled. The metered dose
nasal inhaler operated similarly.
The medicine is refrigerated be-
tween applications. Morning
electrolytes were checked three
days after initiation of therapy.
Patients or parents kept a diary of
the wet and dry nights. During
this time there were no other lim-
itations of fluid intake. Follow-up
and dosage increases were per-
formed at clinic visits and by tele-
phone. After the child
maintained nighttme dryness for
six to 12 months, the families
were encouraged to decrease the
doses and frequency of adminis-
tration of the DDAVP. A satisfac-
tory result was defined as
complete nighttime dryness or a
decrease in the number of re-
corded wet nights.
Results
Dose levels of 10 p.g or less pro-
duced satisfactory results in 81 % of
patients (Figure 1 ) . During treat-
ment, 54% of the children
achieved dryness every night and
38% had a decrease in the number
of wet nights per week (Figure 2).
No one relapsed on treatment
after reaching an effective dose.
Only 8% of the patients had no
improvement on DDAVP. At the
present time, 52 patients are still
taking DDAVP, four relapsed when
taken off medication, and three
are completely dry since being
taken off DDAVP. The range of
serum sodium concentrations was
130 to 140 mEq/L, with a mean of
138 mEq/L. The only complica-
tion was nasal mucosa dryness and
headaches in a single patient after
beginning DDAVP.
The cost at our hospital was
$2.11 per 10-jlg dose (0.1 mL) for
the 2.5-mL bottle preparation, or
$1.67 per 10-J.lg dose of the spray.
The monthly cost (30 nights) of a
5-pg/night course with the liquid
was $31.80, whereas the monthly
cost of a 20-J.lg/night course with
the spray was $100.20.
Discussion
Nocturnal enuresis is multi-
factorial in etiology. Contributing
factors include psychogenic prob-
lems, stress, delayed maturation,
allergy, polydipsia, urinary tract in-
fections, diabetes insipidus, diabe-
tes mellitus, and pinworms. In
1952, Poulton? 7 suggested in-
creased nocturnal production of
urine as a factor in enuresis.
Norgaard et al8 identified noctur-
nal polyuria and abnormal secre-
tion patterns of antidiuretic
hormone secretion in nocturnal
enuretics. That study revealed a
failure of the normal nocturnal in-
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crease in ADH and thereby im-
plicated nocturnal polyuria as a
bedwetting factor. The assumption
is that nocturnal urine volume ex-
ceeds functional bladder capacity
and triggers a voiding contraction.
The higher nocturnal output of
urine is not, by itself, a sufficient
explanation for nocturnal enure-
sis ; these patients also must have a
failure in being awakened by their
full bladders. For this reason, con-
comitant use of an alarm is logical,9
although this was not done in our
series. In 1975, George et all° dem-
onstrated a normal circadian ADH
variation in adult men. Rittig et all
discerned a similar ADH rhythmic-
ity in normal adolescents, an ab-
sence of that variation in enuretic
adolescents, and an increase in the
nocturnal urine output along with
a lower osmolality in adolescents
with enuresis when compared with
normal adolescents. Secretion
patterns of ADH have not been
studied in younger patients with
nocturnal enuresis. Although we
found good responses during treat-
ment, our relapse rate was similar to
that reported by others. 12 Many pa-
tients are so satisfied with DDAVP
that they are reluctant to stop the
medication and thus we have not yet
been able to define a true relapse
rate. We have not tapered the dose
as suggested by some authors.&dquo;
Every bedwetting treatment has
its own drawbacks, in addition to
incomplete efficacy. For siblings
who must share a bedroom, the
alarm is an unhappy choice.
Tofranil can be associated with be-
havioral changes and has a narrow
safety-to-lethal dose gap.l4
Anticholinergics can cause
flushing, dryness, and behavioral
changes. Behavioral therapy is
not an easily identifiable treat-
ment for most practitioners.
DDAVP is effective in the substan-
tial subgroup of patients with noc-
turnal enuresis with abnormal
ADH secretion patterns. The side
effects of DDAVP appear to be few,
but real. 5,lS,16
Our results with DDAVP are
not significantly different than
those reported for use of an
alarm, although our experience
with alarms falls short of pub-
lished success rates. 17,18 We have
used small doses of DDAVP with
results similar to those obtained
with larger doses. The drug is ex-
pensive, and for that reason alone
the least amount necessary
should be useful. On the other
hand, the spray application,
which delivers a minimum of 10
gg (0.1 mL) requires much less
patient instruction and is less ex-
pensive per microgram than the
liquid. Although the costs of med-
ication may be daunting, one
must consider the costs of dia-
pers, extra laundry, and ruined
mattresses to place DDAVP in ap-
propriate context. Even in lower
doses than recommended, DDAVP
is an effective and satisfactory alter-
native to other forms of treatment
of nocturnal enuresis in children
eight years of age and older.
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